Abstract 1611P
Background
Living with brain metastasis (BM) causes distress for patients and family carers. Patients report a wide range of physical, social and psychological problems that affect daily life for them and their families. Despite the high prevalence of BM, little is known about the experiences of family carers. This qualitative study explores how family carers of BM patients perceive the information and communication about diagnosis, the health care services provided, and how their lives are affected by the BM.
Methods
This was a prospective qualitative study with individual semi-structured interviews. Participants were interviewed three times; shortly after the BM diagnosis, and then after two and four months. A total of 40 interviews with 18 adult family carers (13 spouses, 2 adult children, 2 siblings) were conducted. Transcripts were analysed using a reflexive thematic analysis. A trajectory matrix was developed for the longitudinal design, searching for overarching themes over time as well as changes in the themes identified.
Results
For many family carers the BM diagnosis was experienced as particularly frightening, given that the metastases were located in the brain. Family carers felt that they lived in a rapidly changing, chaotic and unpredictable situation. They reported working nonstop to coordinate family life, the patient’s health care follow-up, and to maintain a sort of normality in daily life. The situation affected their relationship with the patient, especially daily life activities and communication. The need for information was extensive among most family carers. They emphasized a need for more information about treatment and prognosis to be able to plan for the future. This information need remained high through all interviews.
Conclusions
Being a family carer of a patient with BM implies extensive practical, emotional and psychosocial challenges. The need for continuous information is particularly high, and health care providers should tailor their information to the individual recipient. Palliative care, with a person-centred approach and systematic follow up of the needs of family carers, should be introduced in an early stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oslo University Hospital.
Funding
The Norwegian Cancer Society Pink Ribbon and The Norwegian South-East Health Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05